Recent Company News

• 04:36 AM ET Jul 03, 2026
  

  Sino Biopharmaceutical receives NMPA acceptance of new drug application for ropivacaine hydrochloride sustained-release solution (HK$4.74, 0.00)

• 11:39 AM ET Jun 29, 2026
  

  China announces preliminary results of 2026 NRDL adjustment, 557 passed for basic medical insurance, 54 passed for commercial insurance list

• 03:54 AM ET Jun 29, 2026
  

  StreetAccount Summary: Hong Kong Stocks reaching new 52-week highs/lows (40 total)

• 11:26 PM ET Jun 28, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (224 total)

• 03:35 AM ET Jun 26, 2026
  

  StreetAccount Summary: Hong Kong Stocks reaching new 52-week highs/lows (54 total)

• 03:38 AM ET Jun 25, 2026
  

  StreetAccount Summary: Hong Kong Stocks reaching new 52-week highs/lows (51 total)

• 03:17 AM ET Jun 24, 2026
  

  StreetAccount Summary: Hong Kong Stocks reaching new 52-week highs/lows (38 total)

• 04:37 AM ET Jun 23, 2026
  

  Sino Biopharmaceutical receives NMPA marketing approval for peceleganan spray (HK$4.42, 0.00)

• 04:04 AM ET Jun 22, 2026
  

  StreetAccount Summary: Hong Kong Stocks reaching new 52-week highs/lows (55 total)

• 06:55 PM ET Jun 15, 2026
  

  Sino Biopharmaceutical presents results from Phase II trial of TQC2938 in patients with moderate-to-severe seasonal allergic rhinitis at EAACI 2026 (HK$4.78, 0.00)